Evidence map›Paper›PMID 36750182›Full record

ArticleAging2023

Interleukin 6 promotes BMP9-induced osteoblastic differentiation through Stat3/mTORC1 in mouse embryonic fibroblasts.

Shi-Yu Wang, Jin-Hai Jiang, Si-Yuan Liu, Jie Zhang, Xiang Gao, Hang Liu, Kai-Xin Ke, Yue Jiang, Lu Liu, Bai-Cheng He

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shi-Yu WangDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Jin-Hai JiangDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Si-Yuan LiuDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Jie ZhangDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Xiang GaoDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Hang LiuDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Kai-Xin KeDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Yue JiangDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Lu LiuDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Bai-Cheng HeDepartment of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin 6 (IL-6) plays a dual role in regulating bone metabolism, although the concrete mechanism is unclear. Bone morphogenetic protein 9 (BMP9) is one of the most potent osteogenic inducers, and a promising alternative for bone tissue engineering. The relationship between IL-6 and BMP9 in osteogenic differentiation remains to be elucidated, and the osteoblastic potential of BMP9 needs to be enhanced to overcome certain shortcomings of BMP9. In this study, we used real-time PCR, western blot, immunofluorescent stain, fetal limb culture and cranial defects repair model to explore the IL-6 role in BMP9-induced osteogenic differentiation in mouse embryonic fibroblasts (MEFs). We found that the rat serum level of IL-6 was increased in the dexamethasone-induced osteoporosis model, and IL-6 expression was detectable in several progenitor cells and MEFs. BMP9 upregulated IL-6 in MEFs, and the BMP9-induced osteoblastic markers were elevated by IL-6, but reduced by IL-6 knockdown. BMP9 and/or IL-6 both activated mTOR, and the IL-6 effect on BMP9-induced osteoblastic markers and bone formation were reduced greatly by mTOR inhibition. Raptor was up-regulated by IL-6 and/or BMP9 specifically, and the osteoblastic markers induced by IL-6 and/or BMP9 were reduced by Raptor knockdown. Meanwhile, Stat-3 was activated by IL-6 and/or BMP9, and the increase of Raptor or osteoblastic markers by IL-6 and/or BMP9 were reduced by Stat-3 inhibition. The Raptor promoter activity was regulated by p-Stat-3. Our finding suggested that IL-6 can promote the BMP9 osteoblastic potential, which may be mediated through activating Stat-3/mTORC1 pathway.

Indexed as

Growth Differentiation Factor 2Interleukin-6AnimalsCell DifferentiationFibroblastsMechanistic Target of Rapamycin Complex 1MiceOsteogenesisRatsSignal TransductionSTAT3 Transcription FactorTOR Serine-Threonine KinasesGrowth Differentiation Factor 2Interleukin-6Mechanistic Target of Rapamycin Complex 1Stat3 protein, mouseSTAT3 Transcription FactorTOR Serine-Threonine Kinasesbone morphogenetic protein 9interleukin 6mammalian target of rapamycin complex 1osteogenic differentiationsignal transducer and activator of transcription 3

Identifiers

PMID36750182
PMCPMC9970304
OpenAlexW4319336292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.